Geiss, Carley
Hoogland, Aasha I.
Arredondo, Brandy
Rodriguez, Yvelise
Bryant, Crystal
Chung, Christine H.
Patel, Krupal B.
Gonzalez, Brian D.
Jim, Heather S. L.
Kirtane, Kedar
Oswald, Laura B.
Article History
Received: 20 November 2023
Accepted: 5 March 2024
First Online: 27 March 2024
Declarations
:
: Dr. Chung receives honoraria from Sanofi and Exelexis for ad hoc Scientific Advisory Board participation. Dr. Gonzalez is a paid consultant for SureMed compliance and KemPharm, and an advisory board member for Elly Health, Inc outside of this work. Dr. Jim is a paid consultant for RedHill BioParma, Janssen Scientific Affairs, and Merck and has grant funding from Kite Pharma outside of this work. Dr. Kirtane owns stock in Seattle Genetics, Oncternal Therapeutics, and Veru. The other authors have no other relevant competing interests to disclose.
: The current research was reviewed by the Institutional Review Board at Advarra and determined to be exempt from oversight due to minimal risk (Pro00045231). All aspects of this study were conducted in accordance with the 1964 Helsinki declaration and later amendments.
: All participants provided verbal consent prior to study enrollment.
: Participants provided verbal consent to have de-identified data published.
: Dr. Chung receives honoraria from Sanofi and Exelixis for ad hoc scientific advisory board participation. Dr. Gonzalez is a paid consultant for Sure Med Compliance and KemPharm, and an advisory board member for Elly Health, Inc., outside of this work. Dr. Jim is a paid consultant for RedHill Biopharma, Janssen Scientific Affairs, and Merck and has grant funding from Kite Pharma outside of this work. Dr. Kirtane owns stock in Seattle Genetics, Oncternal Therapeutics, and Veru. The other authors have no other relevant competing interests to disclose.